Morphomolecular Characterization of Serum Nanovesicles From Microbiomes Differentiates Stable and Infarcted

Camila Rodrigues Moreno1, José Antonio Franchini Ramires2, Paulo Andrade Lotufo3

  • 1Laboratorio de Patologia Cardiaca, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.

Insights

Pathogenic archaea and infectious microvesicles (iMVs) in the blood are linked to severe acute myocardial infarction (AMI). Smaller extracellular vesicles (EVs) appear protective against atherosclerosis and plaque rupture.

Area of Science:

  • Microbiology
  • Cardiovascular Medicine
  • Biotechnology

Background:

  • Microbial communities influence health and disease, including atherosclerosis.
  • Acute myocardial infarction (AMI) involves plaque rupture with a pro-inflammatory microenvironment.
  • Previous work identified archaeal DNA-positive infectious microvesicles (iMVs) in heart failure patients.

Purpose of the Study:

  • To characterize and quantify serum microbiome extracellular vesicles (EVs) to differentiate coronary artery disease (CAD) clinical outcomes.
  • To investigate the role of archaea and iMVs in severe AMI.
  • To explore the protective potential of smaller EVs.

Main Methods:

  • Morphomolecular techniques were used to analyze the size and content of serum microbiome EVs.
  • Quantification of iMVs, exosomes, and other microvesicles (MVs) was performed.
  • Analysis focused on differentiating between severe AMI, stable atherosclerosis, and healthy control groups.

Main Results:

  • Severe AMI patients showed increased numbers of large iMVs (0.8-1.34 nm) positive for archaeal DNA, *Mycoplasma pneumoniae* antigens, and MMP9.
  • Stable atherosclerotic and healthy groups had higher numbers of smaller EVs (<100 nm, exosomes) and MVs (100-200 nm).
  • These smaller EVs and MVs were associated with entrapping and degrading infectious antigens and MMP9, suggesting a protective role.

Conclusions:

  • A microbiome with pathogenic archaea correlates with high serum iMV levels in AMI patients with poor prognosis.
  • The morphomolecular characterization of serum iEVs shows promise as a prognostic biomarker for CAD.
  • Smaller EVs may play a protective role against atherosclerosis progression and plaque rupture.

Related Concept Videos